Ovizio Imaging System, an innovative quantitative microscopy company specializing in life science solutions, announces today the launch of its new product, the iLine F, an in-line suspension cell-monitoring microscope. In collaboration with global distributor, Applikon, the iLine F is being showcased at booth #74 and #77 at the European Society for Animal Cell Technology congress (ESACT), held in Barcelona from May 31 to June 3.
The iLine F uses a quantitative imaging technique based on Differential Digital Holographic Microscopy (DDHM). The suspension cell-monitoring microscope monitors cell viability and cell density in real-time as well as recording aggregate data and up to 16 morphologic parameters.
With the iLineF, Ovizio reduces costs and changes the way suspension cells are monitored, counted and analyzed. The automated technology means there is no need for manual operation; operators can focus on other projects while the iLine F monitors the culture. The technology also offers increased insight into the cell culture process by continuously collecting quantitative data providing reproducible, reliable results.
The iLine F is an in-line, label free and non-invasive solution with no sampling, no staining and no toxic waste. The technology is designed for bioreactor grown suspension cells. The iLine F is connected to a bioreactor via an innovative disposable fluidics probe, avoiding sample consumption and reducing the risk of contamination.
The launch of the iLine F microscope is the result of a long-term global marketing and distribution agreement between Ovizio and Applikon Biotechnology. This agreement includes a global business development plan and covers customer support, maintenance and additional services.
The addition of the iLine F to the Ovizio product line will secure additional revenue and open up new market opportunities in suspension cell monitoring. Ovizio also benefits from the Applikon partnership, gaining access to its global distribution network and international customer base.
“The iLine F combines the best of both worlds, utilizing Applikon’s bioprocess knowledge and Ovizio’s quantitative microscopy expertise,” said Philip Mathuis, CEO of Ovizio. “It offers a revolutionary solution for cell culture applications, as users benefit from its unique feature: a continuous real-time measurement that streamlines the cell-monitoring process.”
“Our partnership with Ovizio will allow Applikon to bring cutting edge bioprocessing technology to the market and to our existing clients,” said Erik Kakes, co-owner and international sales and marketing director at Applikon. “It also gives us a new way to approach scientists who are continuously looking to optimize their processes and need a solution for cell culture monitoring.”
Ovizio and Applikon are showcasing the iLine F at the ESACT meeting, held in Barcelona from May 31 to June 3. This leading cell culture conference (cell therapy, cell based assays, cell engineering…) attracts around 1,000 participants from both academia and industry each year. The meeting is made up of three main components: a scientific program, trade exhibition and a social program, to give an update on the advances in animal cell technology at both the basic and applied levels and to provide an opportunity for participants to interact.
A ‘Cell counting challenge’, is taking place during the congress to encourage comparisons in accuracy and speed between offline, manual cell counting and in line, automated cell counting with Ovizio iLine F microscope.
Can’t attend ESACT? Don’t miss the webinar: ‘How automation has changed the way we count cells’
June 9, 3pm (CET)
An introduction to the multiple benefits of in-line and label-free cell viability monitoring approach, hosted by Prof Dr. Frank Gudermann, chief scientific officer at Optocell Technologies GmbH&Co.KG and Professor at the University of Applied Sciences, Bielefeld, Germany.